Corporate Strategy (CORP) Intelligence Hub
Real-time accumulated intelligence, primary research, and executive digests for Corporate Strategy (CORP).
Anduril considers Baltimore shipyard for drone boat production
Defense-technology company Anduril Industries is exploring an investment in a Baltimore shipyard to manufacture autonomous drone boats, potentially transforming the facility into a major production hub for unmanned naval vessels. The move reflects rising Pentagon interest in lower-cost, AI-enabled maritime systems to counter growing naval capabilities from adversaries. Anduril has been expanding from software and surveillance towers into hardware, particularly sea and air platforms. If finalized, the project could bring new defense-related jobs to Baltimore and boost regional shipbuilding activity. It may also support U.S. Navy experimentation with large fleets of unmanned surface vessels in future operations.
Read Original Source ↗Pigeon targets US as the new China
Japanese baby goods maker Pigeon is shifting its international growth focus to the U.S., describing the market as its “new China” and preparing a concerted push for higher sales and brand recognition there. The strategy reflects slowing demand and rising competition in China, once Pigeon’s main overseas growth engine. The company now views the U.S. as offering stronger long-term potential, driven by resilient consumer spending on premium childcare products. Pigeon plans increased marketing, expanded product lines and stronger retail partnerships in North America. Investors are watching whether the pivot can offset weaker Chinese momentum and diversify revenue, potentially reshaping the company’s global earnings profile.
Read Original Source ↗AstraZeneca holds talks with Bristol Myers Squibb
AstraZeneca has held preliminary talks with Bristol Myers Squibb over a potential $400bn tie-up, according to the Financial Times, in what would rank among the largest deals in pharmaceutical industry history. Discussions reportedly focus on combining two major drug pipelines and oncology portfolios to create a global powerhouse. The talks remain exploratory, with no formal offer submitted, and both sides declining public comment. Any agreement would face intense antitrust scrutiny in multiple jurisdictions, particularly the US and Europe. Investors and analysts are watching for confirmation, possible rival bids, and political reactions to further sector consolidation.
Read Original Source ↗